Connect with us

Heartland

Anthos Group India launch & 4 reasons why the beauty and wellness industry is turning to CBD

Republished by Plato

Published

on

anthos group - 900x600

Healthcare and wellness trends change constantly. One trend that seems to be spreading across both industries is CBD and Hemp. Commonly known as cannabidiol, CBD has been a debatable topic for years now. Once restricted by outdated legal laws, the spread has reached beauty, skincare, food, supplements, and more.
In 2018, Badal Shah, Shan Umer and an all Indian American team, launched the Anthos Group, a vertically integrated consumer products goods company. Acknowledging the power and science of CBD (cannabidiol), sales skyrocketed and Anthos quickly became the leader in the growing CBD industry. I decided to find out what CBD is, and how the Anthos Group took over the market in such little time. 
What is CBD?
CBD stands for cannabidiol, which is a cannabinoid found in the hemp (cannabis sativa) plant. It is a naturally occurring cannabinoid shown to provide numerous medical and health benefits.
What is the industry scoop on CBD?
In the United States, it is booming. The market size was estimated to hit 7.1 billion in 2019 and 9.3 billion in 2020. While the concept is quite new to the Indian market, it’s interesting to see how companies like Body Shop, Ayurvedic Essentials, Boheco Life, Juicy Chemistry, The Hemp Couture, and Be Hemp enter the CBD space. Ratan Tata and Google India’s managing director Rajan Anandan are among the investors in India’s first startup Bombay Hemp Company (Boheco) in the country to study the medical use of cannabis.

1.   CBD is a Pain Reliever

Morphine, codeine, Oxycodone, and Fentanyl are analgesics that are prescribed by medical doctors. These medicines are pain relievers for mild to severe chronic pain. These drugs are addicting, harmful to your health, and cause many long-term side effects. Research has shown that CBD stimulates the endocannabinoid system (ECS) to promote homeostasis, which helps with pain and decreases the inflammation. Also, the compound strengthens the ECS. 

    2.   It is Nonpsychoactive

    Unlike its cousin used for medicinal purposes, THC (tetrahydrocannabinol), CBD is nonpsychoactive. Meaning, it does not change your behavior or perception. It does not make you high as marijuana does, thus making it very safe to use for all demographics.

    3.   Minimizes Anxiety and Depression

    Anxiety and depression are not a joke. They can happen to everybody. People experiencing these mental conditions undergo drug maintenance, which can be addictive. Today, CBD is being used to treat these medical conditions. CBD was known to increase serotonin production, or happy hormone, helping us boost our mood and behavior. 

    4.   Boosts Athletes’ Performance

    Steroid use in India has been controversial. Steroids promote anabolic effects that increase muscle mass and strength, which is essential to athletes of various sports. While doing their job, steroids have lots of side effects from joint pain, skin issues, increased estrogen, and more. Athletes in India are now turning to natural performance assistance.
    Multiple case studies show that CBD promotes better sleep, strengthens the immune system, speeds up recovery, increases endurance, and relieves pain, which are vital for all athletes.
    I asked the team at the Anthos Group if they’re planning on launching any products in the fitness and athletic space. Cohin Kakar, CMO of the Anthos Group said, “We are excited to bring an innovative fitness brand to market called TIDL, which combines the plant-based therapy that we have perfected through our medical line with exercise science in the form of proven practices like cryotherapy and water-solubility. Our flagship product is a topical spray that gives fitness enthusiasts a cooling relief after a workout while also delivering a powerful package of organic ingredients directly to the source to aid in the recovery of pain and inflammation. The product was enhanced with 360-degree spray technology that allows for full-body application in any angle or direction, and self-absorption to be a true touch-free product.” For more information on this brand, visit http://tidlsport.com/
    The Anthos Group is expanding so fast in the marketplace, and I wanted to understand how.
    The answer was easy. Anthos controls the supply chain. They grow their own hemp, they process their own raw oils, they formulate in-house, they source ingredients from only pharmaceutical-grade facilities. If you control the process every step of the way, you know what exactly is going into the finished product.
    Having to address such medical needs in the health and wellness space makes an entrepreneur like Badal Shah, CEO of Anthos, turn to CBD. Entrepreneurs are not just business-minded but also the minds of the future.
    Leadership is like riding a roller coaster. It has ups and downs and thrilling experiences, but a great leader shouts at the top of his/her lungs while riding. Trying something new will not hurt you. Instead, it will mesmerize you and lead you to something you can take as an achievement or a lesson. Today’s development of CBD products is a gamble, but it turned out to be successful and rewarding for Anthos. Who knew entrepreneurs would be famous figures in the CBD field? I asked the company president, Shan Umer, if Anthos is planning to launch in India. He did not confirm nor deny. However, he did mention they’re exploring regulations. I will keep my fingers crossed. For more information on Anthos please visit www.theanthos.com or email info@theanthos.com
    Disclaimer: The views, suggestions and opinions expressed here are the sole responsibility of the experts. No Forbes India journalist was involved in the writing and production of this article.

    Click here to see Forbes India’s comprehensive coverage on the Covid-19 situation and its impact on life, business and the economy​

    Source: https://www.google.com/url?rct=j&sa=t&url=https://www.forbesindia.com/article/brand-connect/anthos-group-india-launch-4-reasons-why-the-beauty-and-wellness-industry-is-turning-to-cbd/61801/1&ct=ga&cd=CAIyGjA0MDJhMmFhMGQxNjkwOWQ6Y29tOmVuOlVT&usg=AFQjCNGHIAR5GPZGYZ7WdnUWVQMyX2Ku0w

    Heartland

    Watermelon Dream Sauce

    Republished by Plato

    Published

    on

    Visit our community site for vetted suppliers at http://theCBD.place. It’s time that this subject was given more internet exposure. We are here to discuss topics related to medical marijuana and our experiences using CBD. Please do not assume that anyone here is a medical professional.

    Source: https://www.reddit.com/r/CBD/comments/jgxl3l/watermelon_dream_sauce/

    Continue Reading

    Heartland

    Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

    Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of […]

    The post Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals appeared first on CannabisFN.

    Republished by Plato

    Published

    on



    Ryan Allway

    October 23rd, 2020

    Psychedelics


    Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle (“GelMA-MN”) delivery technology developed at the University of California, Los Angeles (“UCLA”) for use with psychedelic pharmaceuticals, including, but not limited to Psilocybin, Ketamine, Ibogaine, LSD, MDMA, DMT, and Cannabinoids.

    “We are very pleased to have acquired the rights to this novel microneedle delivery technology as it strengthens the foundation of our strategy to develop and commercialize a unique pipeline of psychedelic pharmaceuticals for FDA approval and I believe puts us in the conversation with companies such as Compass Pathways and Mind Medicine, who are leading the way in psychedelic medicines,” said Fabio Chianelli, Chief Executive Officer of Pharmather. “The GelMA-MN delivery technology is complementary to our approach in finding new uses and combinations of psychedelics to improve therapeutic and safety outcomes while potentially offering a differentiated product profile, improving patient compliance and enabling out-patient treatment options. We are focused on realizing the potential of the GelMA-MN delivery technology and it will open up new market opportunities in multi-billion dollar categories such as mental health, nervous system disorders, pain, skin cancer, wounds, mucosal diseases and surgical applications.”

    “We are pleased to partner with Pharmather and to realize the commercial potential of the GelMA-MN delivery technology as a unique delivery system for treating unmet medical needs,” said Dr. Ali Khademhosseini, Co-Founder of BioRAE, Inc. and Co-Inventor of GelMA-MN delivery technology.

    About GelMA-MN Delivery Technology

    The GelMA-MN (Figure 1) delivery technology was invented and developed by the members of the Khademhosseini Lab at UCLA. Studies have shown that GelMA can be used for the fabrication of MN arrays and the delivery of both water-soluble and insoluble drugs with desirable release profiles. GelMA is derived from the natural polymer gelatin with crosslinkable methacrylate group making it an ideal candidate for MN fabrication and various other biomedical applications. The GelMA-MNs are biocompatible and biodegradable, can efficiently penetrate the stratum corneum layer (outer layer of the skin), enable flexible drug load capacity and combinations, and control-release delivery. MNs are considered as a promising way to achieve systemic effects by transdermal delivery of drugs. In addition to applications on the skin, MNs may be applied in other organs and tissues like the eyes and mucosal surfaces. MNs are minimally invasive, painless, and may overcome the potential drawbacks of oral administration, subcutaneous injections and other transdermal delivery systems.

    Under the terms of the Agreement, the Company gained exclusive worldwide rights to intellectual property to develop and commercialize the GelMA-MN delivery technology with psychedelics, cannabinoids, and various compounds for therapeutic uses. Consistent with industry standards, Pharmather will pay a one-time fee for entering into the Agreement and all other future payments will be based on clinical trial and revenue milestones reached by Pharmather in the future.

    About Pharmather Inc.

    Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. Our goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, traumatic brain injury and stroke. Learn more at: pharmather.com and follow us on FacebookTwitter and LinkedIn.

    This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

    Ryan Allway

    About Ryan Allway

    Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


    Source: https://www.cannabisfn.com/pharmather-secures-exclusive-rights-to-novel-microneedle-delivery-technology-for-psychedelic-pharmaceuticals/

    Continue Reading

    Heartland

    Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health

    Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health. The […]

    The post Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health appeared first on CannabisFN.

    Republished by Plato

    Published

    on



    Ryan Allway

    October 23rd, 2020

    Psychedelics


    Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health.

    The Epiphany360 platform has been clinically validated on more than 10,000 patients over the last 20 years. Four feasibility studies are currently underway, the protocols of which have been designated ‘non-significant risk.’ The data being collected will form part of Epiphany360’s submission to the FDA for clearance as a Class II medical device.

    “We are accelerating our move into digital therapeutics with the Epiphany360 platform to bring evidence-based insights in the diagnoses and treatment of patients suffering from mental health related illness,” stated Philip Tapley, Mind Cure Chairman, President, and CEO. “Technology innovation has a key role to play in modern healthcare as we look to find new and more effective ways to treat mental health. Epiphany360 will enable Mind Cure to more effectively create and evaluate products, drugs and therapies.”

    Dr. Antonio Ocana, the Founder of Epiphany360, said, “We created the Epiphany360 platform to address the devastation experienced by individuals, families and society in the wake of the tragedy associated with mental health and addiction. It’s like a dream come true to work side by side with Mr. Tapley and the Mind Cure team. Together we will optimize the technology that will finally co-ordinate care between doctors, therapists and patients, ultimately, making these solutions accessible to researchers, employers and insurers who will benefit from the improved outcomes and lower healthcare costs. We feel very lucky to have Mind Cure’s scientific advisory team alongside as we move towards regulatory approval.”

    The mental health crisis, made worse by COVID-19, is impacting hundreds of millions of people, lowering productivity and increasing absenteeism and disability, the global burden of which is estimated at more than $1 trillion annually. Mind Cure believes that the application of digital therapeutics can unlock immense value, both enhancing patient access and engagement, as well as making mental health treatment safer and more effective.

    About Epiphany360

    Epiphany360 is a proprietary and cloud-based digital therapeutics platform. It monitors, collects and generates evidence-based insights to optimize treatment and improve patient outcomes in mental health-related conditions. It is powered by proprietary software that compares treatments and outcomes to continuously improve the validity and accuracy of unique patient care options and is backed by 25 years of clinical experience and scientific data.

    Four feasibility studies are currently underway, the protocols of which have been designated ‘non-significant risk.’ The data being collected will form part of Epiphany360’s submission to the FDA for clearance as a Class II medical device.

    About Mind Cure Health Inc.

    Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.

    Pursuant to the LOI, the parties intend to negotiate the terms of a definitive agreement (the “Definitive Agreement“), which will provide for, among other things the acquisition by Mind Cure of substantially all the assets of Epiphany360 in exchange for $2,000,000 of common shares in the capital of Mind Cure based on the ten day volume weighted average price of Mind Cure’s common shares on the Canadian Securities Exchange immediately prior to the closing date (the “Purchase Shares“). The Purchase Shares will be subject to an escrow agreement to be released as follows: 15% released immediately at closing, and the balance to be released in six equal installments every six months for 36 months. There can be no assurance that the Definitive Agreement will be entered into or that the acquisition will be completed on the terms proposed in the LOI or at all.

    This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

    Ryan Allway

    About Ryan Allway

    Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


    Source: https://www.cannabisfn.com/mind-cure-announces-loi-for-acquisition-of-epiphany360-digital-therapeutics-platform-for-treating-mental-health/

    Continue Reading
    Heartland3 days ago

    Web site credit card processing

    Manufacturing2 days ago

    New and Noteworthy Categories on Thomasnet.com for October 2020

    Heartland3 days ago

    CBG Study Shows Antimicrobial Properties of Cannabis

    Heartland2 days ago

    Medical Marijuana: 7 Incredible Health Benefits for Women

    Heartland2 days ago

    German Cannabis Flower Market is Ready to Explode

    CBD4 days ago

    CBD and Geriatric Medicine: Should Seniors Take CBD?

    Heartland4 days ago

    CBG tinctures

    Heartland4 days ago

    Best CBD topical for Trigger Points?

    Heartland4 days ago

    Where do I start for depression?

    Heartland3 days ago

    Find your perfect sleep system

    Heartland2 days ago

    Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector

    Heartland4 days ago

    CBD for anxiety/sleep

    CBD4 days ago

    CBD News: Hemp Industry Daily launches annual industry survey for business data

    Heartland4 days ago

    CBD & Cannabis for Endometriosis

    Heartland2 days ago

    Thanks to these CBD “cigarettes” I am a full week tobacco/nicotine free 🎉

    Heartland1 day ago

    Dosage for CBG/CBD tincture from LN?

    Heartland4 days ago

    Caught my Jack-o’-lantern enjoying a CBD joint

    Heartland5 days ago

    Took too much CBD oil three days ago and still feeling the effects

    Heartland5 days ago

    Natural d hist and CBD oil/ insomnia

    Uncategorized5 days ago

    7 Ways to Celebrate Halloween Responsibly With Cannabis

    Heartland4 days ago

    The Daily Hit: October, 19th 2020

    Manufacturing3 days ago

    Look ! so lovely and warm smile@v@

    Heartland2 days ago

    Will I get high from a gummy with 4.5 mg cbd and .5 mg thc? I have no tolerance.

    Heartland1 day ago

    Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting

    Heartland5 days ago

    High Times Greats: Divine

    Heartland5 days ago

    Havn Life Applies for License to Produce and Sell Psilocybin

    Heartland5 days ago

    CBD Vape Carts

    Heartland5 days ago

    What CBD/hemp flower reviewers do you trust?

    Heartland4 days ago

    Very high volume CBD users – any withdrawal symptoms?

    Heartland4 days ago

    Brand Spotlight: Cannabiotix

    Trending

    A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America